Dynamic Technology Lab Private Ltd purchased a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL) during the first quarter, Holdings Channel reports. The firm purchased 10,871 shares of the biotechnology company’s stock, valued at approximately $236,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Old Mutual Global Investors UK Ltd. raised its position in Exelixis by 237.5% in the first quarter. Old Mutual Global Investors UK Ltd. now owns 5,041,260 shares of the biotechnology company’s stock valued at $109,244,000 after buying an additional 3,547,665 shares during the last quarter. Norges Bank acquired a new position in Exelixis during the fourth quarter valued at $36,882,000. Wells Fargo & Company MN raised its position in Exelixis by 167.1% in the first quarter. Wells Fargo & Company MN now owns 1,460,194 shares of the biotechnology company’s stock valued at $31,642,000 after buying an additional 913,454 shares during the last quarter. Bank of New York Mellon Corp raised its position in Exelixis by 7.3% in the first quarter. Bank of New York Mellon Corp now owns 1,264,985 shares of the biotechnology company’s stock valued at $27,412,000 after buying an additional 86,522 shares during the last quarter. Finally, Allianz Asset Management AG raised its position in Exelixis by 30.2% in the fourth quarter. Allianz Asset Management AG now owns 1,091,543 shares of the biotechnology company’s stock valued at $16,274,000 after buying an additional 253,123 shares during the last quarter. 80.69% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Exelixis, Inc. (NASDAQ EXEL) opened at 19.26 on Friday. The firm has a 50-day moving average price of $20.44 and a 200-day moving average price of $19.81. The stock has a market cap of $5.63 billion, a P/E ratio of 917.14 and a beta of 1.98. Exelixis, Inc. has a 52 week low of $7.20 and a 52 week high of $24.85.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Monday, May 1st. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.01) by $0.06. Exelixis had a return on equity of 126.82% and a net margin of 1.37%. The firm had revenue of $80.90 million for the quarter, compared to the consensus estimate of $65.23 million. During the same quarter last year, the business posted ($0.27) EPS. The company’s revenue for the quarter was up 425.3% on a year-over-year basis. On average, equities research analysts predict that Exelixis, Inc. will post $0.18 EPS for the current year.

WARNING: “10,871 Shares in Exelixis, Inc. (EXEL) Acquired by Dynamic Technology Lab Private Ltd” was posted by Financial Market News and is the property of of Financial Market News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.financial-market-news.com/2017/06/17/10871-shares-in-exelixis-inc-exel-acquired-by-dynamic-technology-lab-private-ltd.html.

Several research analysts recently weighed in on EXEL shares. William Blair reissued an “outperform” rating on shares of Exelixis in a research report on Wednesday, March 1st. Oppenheimer Holdings, Inc. started coverage on Exelixis in a research report on Monday, June 12th. They set a “hold” rating on the stock. Needham & Company LLC started coverage on Exelixis in a research report on Friday, March 31st. They set a “buy” rating and a $28.00 price target on the stock. Cann started coverage on Exelixis in a research report on Wednesday, March 15th. They set a “positive” rating on the stock. Finally, TheStreet raised Exelixis from a “d” rating to a “c+” rating in a research report on Tuesday, May 2nd. Five analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $18.37.

In other Exelixis news, Director Carl B. Feldbaum sold 32,988 shares of Exelixis stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $21.58, for a total value of $711,881.04. Following the sale, the director now owns 52,721 shares of the company’s stock, valued at approximately $1,137,719.18. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Vincent T. Marchesi sold 10,000 shares of Exelixis stock in a transaction dated Monday, April 3rd. The shares were sold at an average price of $21.30, for a total value of $213,000.00. Following the completion of the sale, the director now directly owns 130,070 shares in the company, valued at approximately $2,770,491. The disclosure for this sale can be found here. Insiders sold a total of 765,468 shares of company stock worth $16,847,040 in the last three months. Company insiders own 5.10% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL).

Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.